Catalog No.S1908 Synonyms: SCH-13521

For research use only.

Flutamide (SCH-13521) is an antiandrogen drug, with its active metablolite binding at androgen receptor with Ki values of 55 nM, and primarily used to treat prostate cancer.

Flutamide Chemical Structure

CAS No. 13311-84-7

Selleck's Flutamide has been cited by 15 publications

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Other Androgen Receptor Products

Biological Activity

Description Flutamide (SCH-13521) is an antiandrogen drug, with its active metablolite binding at androgen receptor with Ki values of 55 nM, and primarily used to treat prostate cancer.
Androgen Receptor [1]
55 nM(Ki)
In vitro

Flutamide (Eulexin) is an antiandrogen drug. Flutamide-OH, the active metabolite of flutamide, directly binds at rat anterior pituitary androgen receptor with Ki values of 55 nM. [1] Flutamide does not affect the proliferation of an androgen-sensitive clone of the mouse mammary carcinoma Shionogi SC-l 15 cells in culture, shows only antiandrogenic effect, but not androgenic effect. [2] Flutamide provides treatment for prostate cancer when used along with leuprolide. [3]

In vivo Flutamide causes a markedly reduction in rat ventral prostate weight from 319 mg to 245 mg. A combination of flutamide and LHRH agonist induces an additive effect with a decrease in prostate weight to 101 mg, and an marked drop in prostatic ODC activity. [4]

Protocol (from reference)

Kinase Assay:[1]
  • Androgen Receptor Assay:

    Aliquots of 100 μl cytosol are incubated at 0-4°C for 18 h with 100 μl of the indicated saturating concentration of [3H]T in the presence or absence of increasing concentrations of nonlabeled T, DHT, flutamide (FLU) or flutamide-OH (FLU-OH). At the end of the incubation, free and bound T are separated by the addition of 200 μl dextran-coated charcoal (1 % charcoal, 0.1% dextran T-70, 0.1% gelatin, 1.5 mM EDTA and 50 mM Tris (pH 7.4)) for 15 min before centrifugation at 2300 × g for another 15 min at 0-4°C. Aliquots (350 μl) of the supernatant are transferred to scintillation vials with 10 ml of an aqueous counting solution before counting in a Beckman LS 330 counter.

Cell Research:[2]
  • Cell lines: androgen-sensitive Shionogi cell
  • Concentrations: ~1 μM
  • Incubation Time: 40 days
  • Method: Effect of flutamide on the growth of an androgen-sensitive clone (SEM-l) of mouse mammary carcinoma Shionogi cells in culture. The cells are incubated up to 40 days in medium (MEM + 2% dextran-coated charcoal extracted fetal calf serum) containing the compounds at a concentration of 1 μM. Media are changed every second day.
Animal Research:[4]
  • Animal Models: Male rat
  • Dosages: 5 mg twice daily, 0.25 ml
  • Administration: s.c.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 276.21


CAS No. 13311-84-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01889199 Recruiting Drug: Flutamide|Other: Placebo Polycystic Ovary Syndrome (PCOS) University of California Los Angeles|Oregon Health and Science University April 2013 Phase 2
NCT02341404 Completed Drug: 2-hydroxyflutamide (2-HOF) Prostate Cancer Lidds AB|Uppsala University May 2012 Phase 2
NCT00006214 Completed Drug: flutamide|Other: placebo Prostate Cancer Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) August 2000 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Flutamide | Flutamide ic50 | Flutamide price | Flutamide cost | Flutamide solubility dmso | Flutamide purchase | Flutamide manufacturer | Flutamide research buy | Flutamide order | Flutamide mouse | Flutamide chemical structure | Flutamide mw | Flutamide molecular weight | Flutamide datasheet | Flutamide supplier | Flutamide in vitro | Flutamide cell line | Flutamide concentration | Flutamide nmr